The need for deep student engagement became clear at Dartmouth Geisel School of Medicine when a potential academic-integrity issue revealed gaps in it ...

Avidity's delpacibart etedesiran (del-desiran) was granted orphan drug status in Japan as a treatment for myotonic dystrophy type 1 (DM1).